

**Table S1. Clinical and laboratory data of the CLL patients studied.**

<b>Individual Nr.</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>
<b>PB lymphocytes (% of leukocytes)</b>	98	99	98	94
<b>Prior treatment</b>	no	yes	yes	no
<b>SF3B1 variant frequency* (%)</b>	45	52	0	0
<b>SF3B1 CDS variant</b>	c.2098A>G	c.2098A>G	none	none
<b>SF3B1 AA variant</b>	p.K700E	p.K700E	none	none
<b>TP53 variant frequency (%)</b>	30	44; 12	32; 25	80
<b>TP53 CDS variant</b>	c.808T>C	c.702_710del CAACTACAT; c.742C>T	c.617T>A; c.695_719del25	c.712T>G
<b>TP53 AA variant</b>	p.F270L	p.Y234*; p.R248W	p.L206*; p.I232fs*6	p.C238G
<b>BRAF variant frequency (%)</b>	0	49	0	0
<b>BRAF CDS variant</b>	none	c.1406G>C	none	none
<b>BRAF AA variant</b>	none	p.G469A	none	none
<b>NOTCH1 variant frequency (%)</b>	0	0	50	0
<b>NOTCH1 CDS variant</b>	none	none	c.7544_7545del CT	none
<b>NOTCH1 AA variant</b>	none	none	p.P2515fs*4	none

\*Variant frequencies as determined by 454 sequencing are provided.

PB = peripheral blood, CDS = coding sequence, AA = amino acid.